Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?
Holt
Andrew
A
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology* / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001665:Binding Sites / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D003000:Clonidine / Q000494:pharmacology* / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D054755:Imidazoline Receptors; D008995:Monoamine Oxidase / Q000378:metabolism*; D011955:Receptors, Drug / Q000187:drug effects* / Q000378:metabolism*; D015398:Signal Transduction; D014363:Tryptamines / Q000494:pharmacology / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000928:Antidepressive Agents; D054755:Imidazoline Receptors; D011955:Receptors, Drug; D014363:Tryptamines; C030820:tryptamine; D008995:Monoamine Oxidase; D003000:Clonidine